Date:	Meeting:	
Item No.		
Public	Private	
Author		
Bill Lovell : D	eputy CFO	
GB Lead		
Keiran Lapp	in : Interim CFO	

REPORT TITLE: Finance Report Month 2 2016	-17
DECISIONS TO BE MADE:	
The Governing Body is requested to note receive this report.	and
receive this report.	

Continue to improve the quality of services	Improve patient experience	
Reduced unwarranted variations in services	Reduce the inequalities gap in North Lincolnshire	
Deliver the best outcomes for every patient	Statutory/Regulatory	

#### **Executive Summary (Question, Options, Recommendations):**

The CCG is facing a significant challenge in 2016/17 to meet its financial targets, and the CCG's main priorities will be to:

- Deliver robust contract monitoring of all contracts (but especially of All Acute hospital contracts, and for NLAG in particular).
- Implement, develop and monitor sufficient QIPP scheme savings in 2016/7, to mitigate any contract over-trades which materilise.

The Governing Body is requested to note and receive this report.

Equality Impact	N	
Sustainability	2	
Risk	Υ	See Appendix 3
Legal	Υ	Progress report on meeting Statutory Financial Duties
Finance	Υ	Finance update based on Month 2 2016/17 initial data

Patient, Public, Clinical and Stakeholder Engagement to date									
	N/A	Y	N	DATE		N/A	Y	N	DATE
Patient:					Clinical:				
Public:					Other:				

# FINANCE REPORT 2016/17: FOR THE YEAR TO DATE ENDING 31 MAY 2016 (PERIOD 2)

#### 1) Executive Summary

- At Month 2, the CCG's first financial information of 2016/17 indicates that the CCG is currently on course, in the absence of further action, for a year end overspend of circa £4.416 million (See **Appendix 1** for details).
- However, it is important to note that action is being taken (as outlined below) to address this overspend, so that the CCG meets it financial duties for 2016/17.
- Aside from provisional Contract monitors for Hospital services, the CCG is still awaiting formal details of financial performance in a number of key areas including Prescribing as well as for Acute hospital services.
- The CCG's ability to meet its financial targets in 2016/17 will be primarily reliant on the following key factors:
  - Delivery of the CCG's existing QIPP programme.
  - Sound contract management of all acute contracts but especially the NLAG contract.
  - The identification of further QIPP extensions to meet the potential cost pressure that has resulted from the NLAG contract settlement, post arbitration.

#### 2) Key Points

#### 1. Achievement of Statutory Targets.

As a result of the initial failure to agree a contract with NLAG NHS FT, prior to embarking on an arbitration settlement, the CCG now possesses the following contract with NLAG:

Contract Floor
 Indicative Contract Value
 Contract Ceiling
 £99.4m
 £106.8m
 £108.9m

The CCG's delivery of its financial targets in 2016/17, is explicitly based on achieving a year end contract outcome of £99.4m with NLAG.

In order to curtail NLAG expenditure to as close to £99.4m as possible, the CCG is adopting formal contract management procedures in respect of the NLAG NHS FT contract.

In particular, this will mean that payments will be made strictly in accordance with the NHS standard contract, based on national (SuS) data flows with all relevant contract penalties enacted and deducted.

#### 2. QIPP.

Though Acute contract penalties will assist the CCG in reducing its expenditure down to levels that are compatible with achieving financial balance, they will not be sufficient in themselves to achieve this goal.

Attached at **Appendix 2** is the list of existing QIPP schemes which the CCG developed for the start of 2016/17. **Appendix 3** details the QIPP extensions that will be required to:

- Replace (in full or part) any QIPP schemes which fail to deliver in 2016/17 as originally planned.
- Replace (in full or in part) any QIPP schemes which require joint working with NLAG in particular, where agreement on implementation fails to occur in practice.
- Bridge any potential increase in PBR (Payment By Results)
   activity which threatens to take the CCG's contract value with
   NLAG in excess of affordable limits.

In 2015/16 it is important to recall that the CCG's QIPP programme significantly failed to deliver cash releasable savings , and it is vital that the 2016/17 QIPP programme is successful for the CCG to stand any change of reaching its financial targets.

The CCG should begin to receive robust financial information from Month 3 of 2016/17, and it is important that QIPP progress is explicitly monitored.

#### 3. Conclusion & Recommendation

The CCG is facing a significant challenge in 2016/17 to meet its financial targets, and the CCG's main priorities will be to:

- Deliver robust contract monitoring of all contracts (but especially of All Acute hospital contracts, and for NLAG in particular).
- Implement, develop and monitor sufficient QIPP scheme savings in 2016/7, to mitigate any contract over-trades which materilise.

The Governing Body is requested to note and receive this report.

## NORTH LINCOLNSHIRE CCG - COMMISSIONING OPERATING COST STATEMENT 2016/17

001111		YEAF	R TO DATE - MAY 2	2017	FULL Y	YEAR FORECAST	2016/17
COMM	ISSIONED SERVICES	LATEST BUDGET	ACTUAL	VARIANCE	LATEST BUDGET	ACTUAL	VARIANCE
1	ACUTE SERVICES	£ 000s	£ 000s	£ 000s	£ 000s	£ 000s	£ 000s
1	Northern Lincolnshire & Goole Hospitals NHS FT	13,917	14,653	736	83,503	87,917	4,414
2	Hull & East Yorkshire NHS Trust	1,859	1,859	0	11,157	11,157	0
3	Doncaster & Bassetlaw NHS FT	573	553	(20)	3,439	3,439	0
4	Sheffield Teaching Hospitals NHS FT	212	212	0	1,271	1,271	0
5	Sheffield Children's Hospital NHS FT	74	74	0	443	443	0
7	United Lincolnshire Hospitals NHS Trust	143 132	130	(13)	858 791	858 791	0
8	Leeds Teaching Hospitals NHS Trust East Midlands Ambulance Trust	865	132 865	0	5,193	5,193	0
9	Other Secondary & Tertiary Care Services	309	327	18	1,854	1,854	0
10	Exclusions / Non-Contract Activity	414	405	(9)	2,482	2,482	0
11	Resilience	185	185	Ó	1,110	1,110	0
		18,683	19,395	712	112,101	116,515	4,414
2	MENTAL HEALTH						
12	Rotherham, Doncaster & South Humberside Foundation Trust	2,232	2,269	37	13,390	13,390	0
3	COMMUNITY HEALTH SERVICES	2,232	2,269	37	13,390	13,390	0
13	NLAG Community Services	2,868	2,868	0	17,207	17,207	0
14	Other Community Based Services	575	640	64	3,453	3,453	0
15	Hospices	173	173	0	1,040	1,040	0
16	Voluntary Sector	0	0	0	0	0	0
	,	3,617	3,681	64	21,700	21,700	0
4	SERVICES FOR VULNERABLE PEOPLE						
17	CHC Adult Fully Funded	1,925	1,929	4	11,549	11,549	0
18	CHC Adult Joint Funded	320	318	(2)	1,922	1,922	0
19	CHC Assessment & support	111	110	(1)	666	666	0
20 21	CHC Children Funded Nursing Care & Other Care Packages	102 126	85 106	(16)	609 757	609 757	0
22	Mental Health Out of Area	688	710	(20)	4,128	4,128	0
23	Learning Disabilities	235	237	2	1,411	1,411	0
24	Mental Health Pooled Budget	68	78	10	409	409	0
25	Learning Disabilities Pooled Budget	9	9	0	51	51	0
		3,584	3,582	(1)	21,502	21,502	0
5	PRIMARY CARE SERVICES						
26	Prescribing Costs *	5,092	5,157	65	30,554	30,554	0
27 28	Central Drugs Out Of Hours Service	126	122	(4) 0	756 0	756 0	0
29	Home Oxygen Costs	79	76	(2)	471	471	0
30	Local Enhanced Services	198	197	(1)	1,191	1,191	0
31	Primary Care IT	89	89	0	532	532	0
		5,584	5,642	58	33,504	33,504	0
6	OTHER PROGRAMME SERVICES						
32	Pay	19	8	(11)	113	113	0
33	Patient Transport	270	270	0	1,618	1,618	0
34	NHS Property Services	20	50	30 0	119	119	0
35 36	NHS 111 Other Programme Non Pay	57 1,233	57 1,228	(5)	340 7,401	340 7,401	0
37	Contingency	1,233	0	0	1,125	1,125	0
38	Headroom	0	0	0	2,170	2,170	0
39	Reserves	0	0	0	1,874	1,874	0
		1,598	1,613	14	14,760	14,760	0
7	RUNNING COSTS	ļ					
	L. L. F. COU.P. L. L.			-	. =		
40	Including CSU Recharges	628 <b>628</b>	628 <b>628</b>	0	3,767 <b>3,767</b>	3,767 <b>3,767</b>	0
	SURPLUS (TARGET) PER FINANCE PLAN	0	0	0	2,230	2,230	0
	ACTUAL FORECAST DEFICIT (DO NOTHING)	35,926	36,810	885	222,954	227,368	4,414
	MANAGEMENT ACTIONS REQUIRED / RESULTANT DEFICIT	0	-885	0	0	-4,414	0

SCHEME IMPACT 2016/17
Gross Investment Net

### NORTH LINCOLNSHIRE CCG: QIPP / BCF SUMMARY SAVINGS PLAN 2016/17

	Gross	Investment	Net
I ELECTIVE ADMISSIONS	£000s	£000s	£000s
1) Rapid Access Time Limited (RATL) LEAD: Helen Childs (BCF)  Community Based Team focussing on admission prevention. Business case outlines to avoid 1.2 admissions per day based on average 4 day			
length of stay patients. All based on General Medicine patients.	(680)	498	(182)
2) Frail Elderly Assessment Unit (FEAST) & Older Peoples Mental Health Liaison OPMH®LEAD: Helen Childs (BCF)			
To reclassify Inpatient admissions to assessments as these patients will be treated as part of a chair based assessment.			
Estimate impact 2 patients per day all General Medicine patients based on a 2 day LOS cohort.	(1,355)	1,477	122
Also assumes that this will effectively discharge patients avoiding prolonged length of stay thus incurring excess bed day costs in many cases.  Estimated at 973 days.			
3) EMAS Pathway / Fall Prevention LEAD: Helen Childs (BCF) / Julie Killingbeck			
EMAS Response (predominantly Falls and UTIs). Full A&E and Spell avoidance and length of stay at 7 days (no XS days)			
Activity based on business case. A&E Cost based on £91 low level attendance cost as per PA modelling	(377)	0	(377)
Spread across specialties with Majority general med 70%, 20% T&O and 10% Urology			
4) Care Home Liaison / Telehealth LEAD: Helen Childs (BCF)			
Avoid 1 admission per day (source care home) and 2 A&E Attends at £91 as per PA modelling. Assumed these patients have an estimated 2 day	(509)	0	(509)
ength of stay in General Medicine.	(/		
5) Locality Teams LEAD: Helen Childs (BCF)			
The Locality Teams modelling based on 1-2 admissions per day avoided in General Medicine Spells*	(705)	721	16
Investment shown is for all remaining BCF schemes with NLAG not just ILT	(,,,,,)	,	
6) Care Networks <i>LEAD: tbc</i>			
Stretch reduction of Non-Elective activity for 1617 based on the impact of the Primary Care Networks.	(898)	0	(898)
7) 7 Day Social Worker LEAD: Helen Childs (BCF)			
As part of the original PA modelling the impact of the effecting discharge of patients reducing Excess Bed Days. Reallocated some of the impact	(314)	0	(314)
of this scheme into the OPMH so reduced to	(314)	J	(314)
B) Respiratory Redesign <i>LEAD: Rebecca Bowen</i>			
As per current re-specification (Does include Elective Outpatients)	(159)	73	(87)
•19 years COPD and Adult Asthma and associated outpatient attendances	()		
	(4,996)	2,769	(2,228)
VE / PLANNED ADMISSIONS			
D) Dishatos Curay C Land, Debases Davian			
9) Diabetes Super 6 <i>Lead: Rebecca Bowen</i> As per specification and current modelling.			
Amended as per more recent Month 8 data shows a smaller cohort in the baseline. 50% of follow up activity and 10% of news (2/3rd of the gross	(81)	81	0
saving to be re-invested into NLAG to support education and PC support and 1/3 invested into primary care LES			
10) Outpatient Reviews Lead: Jane Ellerton			
As per 1516 specification and current modelling.	(1,910)		(1,910)
11) Outpatient First Attendances: Consultant Connect Lead: Julie Killingbeck			
As per areas in Consultant Connect evidence base, assumption made of these specialties. 15% of Outpatient First Attends	(521)	79	(452)
Costed at £23 Telephone tariff	(531)	/9	(452)
12) Commissioning Intentions - SUBJECT TO REFINEMENT			
Move TURBTs and Kidney Fragmentation to expected. Move Lucentis Injections to expected by delivering excess in PC/OP setting. Take roughly	(336)		(336)
70% of Joint Injections into PC/OP setting	(555)		
13) Gastroscopy Reductions Lead: Rebecca Bowen			
Return to 14/15 outturn levels based on unexpected increase in Q4, Q1	(141)		(141)
	(2,998)	160	(2,839)
NON HOSPITAL SCHE	(2,330)	100	(2,033)
14) Prescribing	(614)		(614
	(027)		(014)
15) Continuing Health Care	/20.11	т	/201
	(304)		(304)
16) Other			
	(33)		(33)
17) Mental Health & LD - Out of Area Risk / Gain Share with RDASH			
	TBC	TBC	TBC
	(054)	0	(054
	(951)	0	(951)
TOTAL	(8,945)	2,928	(6,017)
DOCT ADDITE ATION OIDS SYTEMSIONS	-/F07\		-/503
POST ARBITRATION QIPP EXTENSIONS	(507)	0	(507)
REVISED TOTAL	(9,452)	2,928	(6,524)

## **NORTH LINCOLNSHIRE CCG - RISKS & OPPORTUNITIES AT MAY 2016/17**

2016/17		Probability of	Potential		
	Full Risk	risk being	Risk Value	Proportion	
	Value 15	realised 15	15	of Total 15	
Risks	£'000	%	£'000	%	Commentary 15
CCGs					
Acute SLAs	4,280	50.0%	2,140	28.3%	Includes £1.239m of expenditure related to Re-admissions
Community SLAs			-	0.0%	Plus impact of increasing Elective Activity Growth (including Outpatients by 2% upto 3%.
Mental Health SLAs	1,464	50.0%	732	9.7%	
Continuing Care SLAs			-	0.0%	
QIPP Under-Delivery	7,994	45.0%	3,599	47.5%	
Performance Issues			-	0.0%	
Primary Care			-	0.0%	
Prescribing	2,200	50.0%	1,100	14.5%	
Running Costs			-	0.0%	
BCF			-	0.0%	
Other Risks			-	0.0%	
			•		
TOTAL RISKS	15,938	48%	7,571	100.0%	
	FII	Probability of	Cummatad		
Mitigations	Full Mitigation Value 15 £'000	success of mitigating action 15	Expected Mitigation Value 15 £'000	Proportion of Total 15 %	Commontant/15
Mitigations  Uncommitted Funds (Eyel 1% Hondroom)	Mitigation Value 15	success of mitigating	Mitigation Value 15	of Total 15	Commentary15
Uncommitted Funds (Excl 1% Headroom)	Mitigation Value 15 £'000	success of mitigating action 15 %	Mitigation Value 15 £'000	of Total 15 %	Commentary15
Uncommitted Funds (Excl 1% Headroom) Contingency Held	Mitigation Value 15	success of mitigating action 15	Mitigation Value 15 £'000	of Total 15 % 22.0%	Commentary15
Uncommitted Funds (Excl 1% Headroom)  Contingency Held  Reserves	Mitigation Value 15 £'000	success of mitigating action 15 %	Mitigation Value 15 £'000	of Total 15 % 22.0% 0.0%	Commentary15
Uncommitted Funds (Excl 1% Headroom) Contingency Held Reserves Investments Uncommitted	Mitigation Value 15 £'000	success of mitigating action 15 %	Mitigation Value 15 £'000	of Total 15 % 22.0% 0.0% 0.0%	Commentary15
Uncommitted Funds (Excl 1% Headroom)  Contingency Held  Reserves Investments Uncommitted  Uncommitted Funds Sub-Total	Mitigation Value 15 £'000	success of mitigating action 15 %	Mitigation Value 15 £'000	of Total 15 % 22.0% 0.0%	Commentary15
Uncommitted Funds (Excl 1% Headroom) Contingency Held Reserves Investments Uncommitted	Mitigation Value 15 £'000	success of mitigating action 15 %	Mitigation Value 15 £'000	of Total 15 % 22.0% 0.0% 0.0%	Commentary15  £1m Movement in Elective Activity from NLAG (N.b. less than 2015/16 covered in other contract plans),
Uncommitted Funds (Excl 1% Headroom)  Contingency Held  Reserves Investments Uncommitted  Uncommitted Funds Sub-Total	Mitigation Value 15 £'000	success of mitigating action 15 %	Mitigation Value 15 £'000	of Total 15 % 22.0% 0.0% 0.0%	
Uncommitted Funds (Excl 1% Headroom)  Contingency Held  Reserves Investments Uncommitted  Uncommitted Funds Sub-Total	Mitigation Value 15 £'000	success of mitigating action 15 %	Mitigation Value 15 £'000	of Total 15 % 22.0% 0.0% 0.0%	£1m Movement in Elective Activity from NLAG (N.b. less than 2015/16 covered in other contract plans),
Uncommitted Funds (Excl 1% Headroom)  Contingency Held  Reserves Investments Uncommitted  Uncommitted Funds Sub-Total	Mitigation Value 15 £'000	success of mitigating action 15 %	Mitigation Value 15 £'000	of Total 15 % 22.0% 0.0% 0.0%	£1m Movement in Elective Activity from NLAG (N.b. less than 2015/16 covered in other contract plans), £500k Procedures with Ltd Clinical Value, £1m Commissioning Pathway Re-design (Unwarranted
Uncommitted Funds (Excl 1% Headroom)  Contingency Held  Reserves Investments Uncommitted  Uncommitted Funds Sub-Total  Actions to Implement	Mitigation Value 15 £'000	success of mitigating action 15 % 100.0%	Mitigation Value 15 £'000 1,125 - - 1,125	of Total 15 % 22.0% 0.0% 0.0% 22.0%	£1m Movement in Elective Activity from NLAG (N.b. less than 2015/16 covered in other contract plans), £500k Procedures with Ltd Clinical Value, £1m Commissioning Pathway Re-design (Unwarranted Variation including EBDs), £2,500k from further Commissioning for Value Initiatives (still being worked
Uncommitted Funds (Excl 1% Headroom)  Contingency Held Reserves Investments Uncommitted  Uncommitted Funds Sub-Total  Actions to Implement  Further QIPP Extensions	Mitigation Value 15 £'000 1,125 1,125	success of mitigating action 15 % 100.0%	Mitigation Value 15 £'000 1,125 - - 1,125 2,500	of Total 15 % 22.0% 0.0% 0.0% 22.0%	£1m Movement in Elective Activity from NLAG (N.b. less than 2015/16 covered in other contract plans), £500k Procedures with Ltd Clinical Value, £1m Commissioning Pathway Re-design (Unwarranted Variation including EBDs), £2,500k from further Commissioning for Value Initiatives (still being worked up)
Uncommitted Funds (Excl 1% Headroom) Contingency Held Reserves Investments Uncommitted Uncommitted Funds Sub-Total Actions to Implement  Further QIPP Extensions Non-Recurrent Measures	Mitigation Value 15 £'000 1,125 1,125	success of mitigating action 15 % 100.0% 100% 50.0% 75.0%	Mitigation Value 15 £'000 1,125 - - 1,125 2,500 1,500	of Total 15 % 22.0% 0.0% 0.0% 22.0% 48.8% 29.3%	£1m Movement in Elective Activity from NLAG (N.b. less than 2015/16 covered in other contract plans), £500k Procedures with Ltd Clinical Value, £1m Commissioning Pathway Re-design (Unwarranted Variation including EBDs), £2,500k from further Commissioning for Value Initiatives (still being worked up)
Uncommitted Funds (Excl 1% Headroom) Contingency Held Reserves Investments Uncommitted Uncommitted Funds Sub-Total Actions to Implement  Further QIPP Extensions Non-Recurrent Measures Delay/ Reduce Investment Plans	Mitigation Value 15 £'000 1,125 1,125 5,000 2,000	success of mitigating action 15 % 100.0%	Mitigation Value 15 £'000 1,125 - - 1,125 2,500 1,500	of Total 15 % 22.0% 0.0% 0.0% 22.0% 48.8% 29.3% 0.0%	£1m Movement in Elective Activity from NLAG (N.b. less than 2015/16 covered in other contract plans), £500k Procedures with Ltd Clinical Value, £1m Commissioning Pathway Re-design (Unwarranted Variation including EBDs), £2,500k from further Commissioning for Value Initiatives (still being worked up) Penalties from the application of PBR rules
Uncommitted Funds (Excl 1% Headroom) Contingency Held Reserves Investments Uncommitted Uncommitted Funds Sub-Total Actions to Implement  Further QIPP Extensions Non-Recurrent Measures Delay/ Reduce Investment Plans Mitigations relying on potential funding	Mitigation Value 15 £'000 1,125 1,125 5,000 2,000	success of mitigating action 15 % 100.0% 100% 50.0% 75.0%	Mitigation Value 15 £'000 1,125 - - 1,125 2,500 1,500 - -	22.0% 0.0% 0.0% 22.0% 48.8% 29.3% 0.0% 0.0%	£1m Movement in Elective Activity from NLAG (N.b. less than 2015/16 covered in other contract plans) £500k Procedures with Ltd Clinical Value, £1m Commissioning Pathway Re-design (Unwarranted Variation including EBDs), £2,500k from further Commissioning for Value Initiatives (still being worked up) Penalties from the application of PBR rules
Uncommitted Funds (Excl 1% Headroom) Contingency Held Reserves Investments Uncommitted Uncommitted Funds Sub-Total Actions to Implement  Further QIPP Extensions Non-Recurrent Measures Delay/ Reduce Investment Plans Mitigations relying on potential funding	Mitigation Value 15 £'000 1,125 1,125 5,000 2,000	success of mitigating action 15 % 100.0% 100% 50.0% 75.0%	Mitigation Value 15 £'000 1,125 - - 1,125 2,500 1,500 - -	22.0% 0.0% 0.0% 22.0% 48.8% 29.3% 0.0% 0.0%	£1m Movement in Elective Activity from NLAG (N.b. less than 2015/16 covered in other contract plans £500k Procedures with Ltd Clinical Value, £1m Commissioning Pathway Re-design (Unwarranted Variation including EBDs), £2,500k from further Commissioning for Value Initiatives (still being worked up) Penalties from the application of PBR rules
Uncommitted Funds (Excl 1% Headroom) Contingency Held Reserves Investments Uncommitted Uncommitted Funds Sub-Total Actions to Implement  Further QIPP Extensions Non-Recurrent Measures Delay/ Reduce Investment Plans Mitigations relying on potential funding Actions to Implement Sub-Total	Mitigation Value 15 £'000 1,125 1,125 5,000 2,000	success of mitigating action 15 % 100.0% 100% 50.0% 75.0%	Mitigation Value 15 £'000 1,125 - - 1,125 2,500 1,500 - - 4,000	48.8% 29.3% 0.0% 78.0%	£1m Movement in Elective Activity from NLAG (N.b. less than 2015/16 covered in other contract plans, £500k Procedures with Ltd Clinical Value, £1m Commissioning Pathway Re-design (Unwarranted Variation including EBDs), £2,500k from further Commissioning for Value Initiatives (still being worked up) Penalties from the application of PBR rules

31.3%

(2,446)

NET RISK / HEADROOM